Safinamide Applications in Parkinson's Disease Management

Safinamide is a reversible monoamine oxidase B inhibitor endowed with additional sodium‐channel blocking and glutamatergic modulation properties. Licensed as an adjunct to levodopa, it targets both dopaminergic and non-dopaminergic pathways to alleviate motor fluctuations and extend ON time. By attenuating excessive glutamate release in basal ganglia circuits, safinamide reduces levodopa-induced dyskinesias and addresses a range of non-motor symptoms, including pain, mood disturbances and autonomic dysfunction. Randomised controlled trials, long-term extensions and real-world studies have confirmed its favourable safety profile and sustained efficacy. Its global uptake reflects versatility across diverse patient subgroups, with emerging evidence on optimal dosing, long-term outcomes and the balance between dopaminergic and non-dopaminergic actions that underlie its therapeutic benefits.

Research from Nature Portfolio

Recent studies have explored gender-specific responses to safinamide in Parkinson’s cohorts. A phase III, double-blind analysis in Chinese patients demonstrated significant reductions in daily OFF time alongside improvements in motor scores and quality-of-life measures for both sexes. Numerically greater gains were observed in female participants for OFF time reduction and Unified Parkinson’s Disease Rating Scale scores, suggesting that sex-related pharmacokinetic or hormonal factors may modulate treatment response. Although statistical power for gender comparisons was limited by sample size, these findings underscore the importance of patient demographics in tailoring safinamide therapy and prompt further investigation into sex-based differences in drug efficacy.

Safinamide Applications in Parkinson's Disease Management publication trend

The graph below shows the total number of articles in safinamide applications in parkinson's disease management across all publications each year (not limited to Nature Index journals).

Technical terms

OFF time: Periods when dopaminergic medication effect wanes and motor symptoms re-emerge.

ON time: Intervals during which medication provides optimal control of motor symptoms.

Monoamine oxidase B inhibitor: Agent that reversibly inhibits MAO-B to reduce dopamine breakdown and prolong its activity.

Glutamatergic modulation: Regulation of glutamate release or receptor function to influence excitatory neurotransmission in basal ganglia pathways.

Dyskinesia: Involuntary, often choreiform movements arising as complications of long-term levodopa therapy.

References

1. The effects of safinamide according to gender in Chinese parkinsonian patients. Scientific Reports (2023).
2. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. Journal of Pharmacology and Experimental Therapeutics (2017).
3. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. Journal of Parkinson’s Disease (2021).
4. Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study. Brain Sciences (2021).
5. Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. Brain Sciences (2021).